Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • ascls.org
    • ascls.org

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society for Clinical Laboratory Science
  • ascls.org
    • ascls.org
  • My alerts
  • Log in
  • My Cart
American Society for Clinical Laboratory Science

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • Follow ASCLS on Twitter
  • Visit ASCLS on Facebook
  • Follow ASCLS on Instagram
  • RSS Feed
Research ArticleFocus: Component Therapy

Developments in Component Therapy: Novel Components and New Uses for Familiar Preparations

Michelle S Wright-Kanuth and Linda A Smith
American Society for Clinical Laboratory Science April 2002, 15 (2) 116-124; DOI: https://doi.org/10.29074/ascls.15.2.116
Michelle S Wright-Kanuth
is Associate Professor, Department of Clinical Laboratory Sciences at the University of Texas Medical Branch, Galveston TX
PhD CLS(NCA)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mskanuth@utmb.edu
Linda A Smith
is Professor and Graduate Program Director at the University of Texas Health Science Center at San Antonio, San Antonio TX
PhD CLS(NCA)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

  1. Michelle S Wright-Kanuth, PhD CLS(NCA)⇑
    1. is Associate Professor, Department of Clinical Laboratory Sciences at the University of Texas Medical Branch, Galveston TX
  2. Linda A Smith, PhD CLS(NCA)
    1. is Professor and Graduate Program Director at the University of Texas Health Science Center at San Antonio, San Antonio TX
  1. Address for correspondence: Michelle S Wright-Kanuth PhD CLS(NCA), Department of Clinical Laboratory Sciences, 301 University Boulevard, Galveston, TX 77555-1140. (409) 772-3055, definitions, clauses (409) 772-9470 (fax). mskanuth{at}utmb.edu

At the end of the article the learner will be able to:

  1. Identify the major diseases treated with each of the components discussed.

  2. Discuss the preparation of DLI and why CD4 cells are retained, while CD8 cells are depleted.

  3. Describe the general process of making a dendritic cell vaccine.

  4. Describe the different types of red cell substitutes and differentiate between them.

  5. Explain at least two of the possible ways in which intravenous immunoglobulins may interact with the immune system.

  6. Explain why cryoprecipitate reduced plasma is effective in treating thrombotic thrombocytopenia.

  7. List and describe the platelet products under development.

Extract

Over the years, the significant role of blood components in treating certain diseases or conditions has been recognized. The use of these components has expanded as patients undergo chemotherapy for bone marrow ablation and require short-term component support. On the other hand, these transfusions can cause reactions ranging from mild to severe. Despite advances in serological testing for infectious disease agents, the risk of infectious complications from transfusion still remains. In addition, newly identified agents that may be transmitted via transfusion are constantly identified.

The cellular components most people are familiar with include packed red blood cells (PRBC), washed PRBC, leukoreduced PRBC, and pooled or apheresis platelets. Plasma products such as fresh frozen plasma (FFP) or crytoprecipitated anti-hemophiliac factor (CRYO), on the other hand, may not be as familiar. As our understanding of how the immune system functions and as technology has progressed, specialized components or manufactured products such as blood substitutes have been advanced as remedies to some of the complications with component transfusion or to meet the ever-increasing need for these products.

In this article we will focus on some of the new uses of common components and uncommonly used or newly developing components. We will discuss their origins, composition, and the conditions or diseases they are used to treat. These components include:

  • donor leukocyte infusions

  • dendritic cell vaccines

  • blood substitutes

  • novel platelet products and substitutes

  • intravenous immunoglobulin (IVIG)

  • fresh frozen plasma and cryosupernatant in therapeutic plasma exchange.

The variety of products and conditions…

ABBREVIATIONS:

AML = acute myeloid leukemia; APT = antigen presenting cell; CML = chronic myeloid leukemia; CRP = cryoprecipitate reduced plasma; CRYO = crytoprecipitated anti-hemophiliac factor; DC = dendritic cell; DCLHb = diaspirin cross-linked hemoglobin; DCLHb = diaspirin cross-linked hemoglobin; DLI = donor lymphocyte infusion; DMSO = dimethylsulfoxide; FFP = fresh frozen plasma; GVHD = graft-versus-host disease; GVL = graft-versus-leukemia; HbOC = hemoglobin-based oxygen carrier; HLA = human leukocyte antigens; IPMs = infusible platelet membranes; IVIG = intravenous immunoglobulin; LEHb = liposomes containing hemoglobin; PAP = prostatic acid phosphatase; PBMC = peripheral blood mononuclear cells; PEG = polyethylene glycol; POE = polyoxyethylene; PRBC = packed red blood cells; TPE = therapeutic plasma exchange.

    INDEX TERMS
  • blood and platelet substitutes
  • blood component therapy
  • blood components
  • novel blood components

At the end of the article the learner will be able to:

  1. Identify the major diseases treated with each of the components discussed.

  2. Discuss the preparation of DLI and why CD4 cells are retained, while CD8 cells are depleted.

  3. Describe the general process of making a dendritic cell vaccine.

  4. Describe the different types of red cell substitutes and differentiate between them.

  5. Explain at least two of the possible ways in which intravenous immunoglobulins may interact with the immune system.

  6. Explain why cryoprecipitate reduced plasma is effective in treating thrombotic thrombocytopenia.

  7. List and describe the platelet products under development.

  • © Copyright 2002 American Society for Clinical Laboratory Science Inc. All rights reserved.
PreviousNext
Back to top

In this issue

American Society for Clinical Laboratory Science: 15 (2)
American Society for Clinical Laboratory Science
Vol. 15, Issue 2
Spring 2002
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Society for Clinical Laboratory Science.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Developments in Component Therapy: Novel Components and New Uses for Familiar Preparations
(Your Name) has sent you a message from American Society for Clinical Laboratory Science
(Your Name) thought you would like to see the American Society for Clinical Laboratory Science web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Developments in Component Therapy: Novel Components and New Uses for Familiar Preparations
Michelle S Wright-Kanuth, Linda A Smith
American Society for Clinical Laboratory Science Apr 2002, 15 (2) 116-124; DOI: 10.29074/ascls.15.2.116

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Developments in Component Therapy: Novel Components and New Uses for Familiar Preparations
Michelle S Wright-Kanuth, Linda A Smith
American Society for Clinical Laboratory Science Apr 2002, 15 (2) 116-124; DOI: 10.29074/ascls.15.2.116
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Keywords

  • blood and platelet substitutes
  • blood component therapy
  • blood components
  • novel blood components

© 2025 The American Society for Clinical Laboratory Science

Powered by HighWire